PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-16.40%
Negative revenue growth while MRVL stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-29.55%
Negative gross profit growth while MRVL is at 0.00%. Joel Greenblatt would examine cost competitiveness or demand decline.
-62.46%
Negative EBIT growth while MRVL is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-62.46%
Negative operating income growth while MRVL is at 0.00%. Joel Greenblatt would press for urgent turnaround measures.
-63.67%
Negative net income growth while MRVL stands at 0.00%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-65.79%
Negative EPS growth while MRVL is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-64.86%
Negative diluted EPS growth while MRVL is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
2.06%
Share change of 2.06% while MRVL is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
-12.19%
Reduced diluted shares while MRVL is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-2.02%
Dividend reduction while MRVL stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-81.83%
Negative OCF growth while MRVL is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-145.60%
Negative FCF growth while MRVL is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
9.31%
10Y CAGR of 9.31% while MRVL is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
-19.03%
Negative 5Y CAGR while MRVL stands at 0.00%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
1.93%
3Y CAGR of 1.93% while MRVL is zero. Bruce Berkowitz would see if small gains can accelerate to a more decisive lead.
72.96%
OCF/share CAGR of 72.96% while MRVL is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
241.61%
OCF/share CAGR of 241.61% while MRVL is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
333.18%
3Y OCF/share CAGR of 333.18% while MRVL is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
403.33%
10Y net income/share CAGR of 403.33% while MRVL is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
20.89%
Net income/share CAGR of 20.89% while MRVL is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
1743.73%
3Y net income/share CAGR of 1743.73% while MRVL is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
305.24%
Equity/share CAGR of 305.24% while MRVL is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
163.29%
Equity/share CAGR of 163.29% while MRVL is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
91.82%
Equity/share CAGR of 91.82% while MRVL is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
5.40%
Dividend/share CAGR of 5.40% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
-0.94%
Negative 5Y dividend/share CAGR while MRVL stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-1.13%
Negative near-term dividend growth while MRVL invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-11.62%
Firm’s AR is declining while MRVL shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-4.30%
Inventory is declining while MRVL stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-2.70%
Negative asset growth while MRVL invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
1.20%
BV/share growth of 1.20% while MRVL is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
-6.60%
We’re deleveraging while MRVL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
1.13%
R&D growth of 1.13% while MRVL is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
-13.22%
We cut SG&A while MRVL invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.